FDA Clearance of IND Application for TACC3 PPI Inhibitor A2A-252 in Women's Cancer

A2A co-founded biomea Fusion raises $56M

Biomea Fusion, Inc., a precision oncology company dedicated to developing innovative medicines targeting genomically defined alterations in both hematologic and solid cancers, announced the closing of a $56 million Series A financing today. The syndicate is led by Cormorant Asset Management with participation from Boxer Capital of Tavistock Group, Janus Henderson Investors, Rock Springs Capital, RTW Investments, LP, Aisling Capital, Point Sur Investors, Logos Capital and Clifton Capital.

READ MORE

A2A / Daewoong Pharmaceutical Oncology Agreement

A2A Pharmaceuticals Inc. Today Announced a Multi-target Co-development Agreement With Daewoong Pharmaceutical for AI-enhanced Oncology Drug Discovery.

LEARN MORE